ONDINE BIOMEDICAL
INC.
("Ondine
Biomedical", "Ondine" or the "Company")
Steriwave in all British
Columbia Health Authorities
Ondine Biomedical Inc. (LON: OBI), a
leading provider of light-activated antimicrobial technology to
prevent and treat hospital infections, is pleased to announce that
Steriwave® nasal decolonization is now being used in all five of
British Columbia's health authorities. This deployment signals
Ondine's increasingly strong presence across the Canadian
healthcare system.
As of 21 August 2024, the University
Hospital of Northern British Columbia (UHNBC) in Prince George, a
major hub for specialized surgical care in Northern BC, has begun
using Steriwave to treat patients undergoing hip and knee
arthroplasties. With this deployment at UHNBC, Steriwave is now
operational in all five of British Columbia's health authorities:
Vancouver Coastal Health, Fraser Health, Vancouver Island Health,
Interior Health, and Northern Health.
Carolyn Cross, CEO of Ondine
Biomedical, commented:
"Our mission is to bring our
non-resistance-forming photodisinfection technology into hospitals
to safeguard patients and healthcare workers from the growing
threat of multidrug resistance and other emerging health
challenges. Steriwave, a simple five-minute treatment that removes
nasal pathogens-the source of many hospital-acquired
infections-plays a crucial role in this effort. The adoption of
Steriwave by the largest hospital in northern British Columbia is a
significant achievement for Ondine. We are proud to be working with
all of BC's health authorities to avoid infections and their
associated human and financial costs."
Canadian hospitals using Steriwave
have reported reduced surgical site infections, decreased
antibiotic use, shorter hospital stays, lower mortality rates,
fewer respiratory infections, significant cost savings, with high
levels of compliance and patient and clinician
satisfaction.
Steriwave nasal photodisinfection is
a non-invasive, light-activated antimicrobial treatment that has
been clinically proven to reduce pathogens in the nasal passages,
thereby lowering the risk of hospital-acquired infections.
Steriwave's rapid action prevents pathogens from developing
resistance, offering an effective alternative to antibiotics. A
2023 study showed that Steriwave is highly effective (>99.99%
kills in 20 seconds) against both moderately drug-resistant (MDR)
and extensively drug-resistant (XDR) pathogens.
Enquiries:
Ondine Biomedical
Inc.
|
|
Carolyn Cross, CEO
|
+001 (604)
665 0555
|
|
|
Singer Capital Markets (Nominated Adviser and Joint Broker)
|
|
Phil Davies, Sam Butcher
|
+44 (0)20
7496 3000
|
|
|
RBC
Capital Markets (Joint
Broker)
|
|
Rupert Walford, Kathryn
Deegan
|
+44 (0)20
7653 4000
|
|
|
Vane Percy & Roberts (Media
Contact)
|
|
Simon Vane Percy, Amanda
Bernard
|
+44 (0)77
1000 5910
|
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a clinical
Canadian life sciences company and leader in light-activated
antimicrobial therapies (also known as 'photodisinfection'). Ondine
has a pipeline of investigational products, based on its
proprietary photodisinfection technology, in various stages of
development.
Ondine's nasal photodisinfection
system has a CE mark in Europe and the UK and is approved in Canada
and several other countries under the name Steriwave®.
In the US, it has been granted Qualified Infectious Disease Product
designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for
a variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns and other
indications.
About Steriwave®
Ondine's Steriwave nasal
photodisinfection system is a patented technology using a
proprietary light-activated antimicrobial (photosensitizer) to
destroy bacteria, viruses, and fungi colonizing the nose. The
photodisinfection treatment is carried out by a trained healthcare
professional and is an easy-to-use, painless, two-step process. The
photosensitizer is applied to each nostril using a nasal swab,
followed by illumination of the area with a specific wavelength of
red laser light for less than five minutes. The light activates the
photosensitizer, causing an oxidative burst that is lethal to all
types of pathogens without causing long-term adverse effects on the
nasal microbiome. A key benefit of this approach-unlike with
antibiotics, which have resistance rates reported as high as
81%[1]-is that pathogens do not develop
resistance to the therapy.
Nasal decolonization is recommended
in the 2016 WHO Global guidelines for the prevention of surgical
site infections,[2] and the Society for
Healthcare Epidemiology of America (SHEA) guidelines, published in
May 2023, recommend nasal decolonization for major surgical
procedures.[3]